BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Short Interest Update

BriaCell Therapeutics Corp. (NASDAQ:BCTXWGet Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 3,200 shares, a growth of 10.3% from the December 15th total of 2,900 shares. Based on an average trading volume of 154,200 shares, the short-interest ratio is currently 0.0 days.

BriaCell Therapeutics Price Performance

Shares of BriaCell Therapeutics stock remained flat at $0.15 during trading on Friday. The stock had a trading volume of 210 shares, compared to its average volume of 111,150. BriaCell Therapeutics has a 52-week low of $0.11 and a 52-week high of $2.30. The firm’s 50-day moving average price is $0.31 and its two-hundred day moving average price is $0.27.

BriaCell Therapeutics Company Profile

(Get Free Report)

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.

Further Reading

Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.